

Bioinformatics analysis of the expression of HOXC13 and its role in the prognosis of breast cancer

CHANGYOU LI*, JUNWEI CUI*, LI ZOU, LIZHANG ZHU and WEI WEI

Department of Breast Surgery, Shenzhen Hospital, Peking University, Shenzhen, Guangdong 518036, P.R. China

Received April 13, 2019; Accepted October 10, 2019

DOI: 10.3892/ol.2019.11140

Abstract. The homeobox (HOX) genes, a class of transcription factors, are known to promote embryonic development and induce tumor formation. To date, the HOXA and HOXB gene families have been reported to be associated with breast cancer. However, the expression and exact role of homeobox C13 (*HOXC13*) in breast cancer has not yet been investigated. In the present study, the *HOXC13* expression in human breast cancer was evaluated using the Oncomine database and Cancer Cell Line Encyclopedia (CCLE). Next, the Gene expression-based Outcome for Breast cancer online database, cBioportal, University of California Santa Cruz Xena browser and bc-GenExMinerv were used to explore the specific expression of *HOXC13* in breast cancer. The methylation and mutation status of *HOXC13* in breast cancer was then validated using the CCLE and cBioportal databases. Finally, the co-expression of HOX transcript antisense RNA (*HOTAIR*) and *HOXC13* in breast cancer were analyzed and their impact on clinical prognosis determined. It was found that the expression of *HOXC13* was high in breast cancer compared with other types of cancer, such as gastric cancer and colon cancer. Following co-expression analysis, a significant positive association was identified between *HOTAIR* and *HOXC13*. An association between *HOTAIR* and *HOXC13*, and lymph node and distant metastasis recurrence was also revealed during the development of breast cancer. Of note, survival analysis showed that high expression of *HOTAIR* and *HOXC13* predicted poor prognosis. These findings revealed that *HOXC13* plays an important role in the progression of breast cancer. However, the specific mechanism needs to be confirmed by subsequent experiments.

Introduction

Breast cancer, the most common type of cancer in women, presents a challenge for global research (1). Molecular research on breast cancer was at a bottleneck, until the identification of a correlation between BRCA1/2 DNA repair associated and breast cancer was reported and marked great progress in the research, treatment and prognosis of breast cancer (2,3). Following this, genetic susceptibility has become the focus of breast cancer research (4). However, in the context of big data, with the development of high-throughput sequencing technology, it is not difficult to find susceptibility genes.

The Homeobox (HOX) genes is a large class of transcription factors that play an important role in embryogenesis and oncogenesis, as well as the distribution of fat and hair in body (5-7). In humans, the HOX gene family contains 39 HOX genes located on 4 different chromosomes (7p15, 17q21.2, 12q13 and 2q31) (8). The 39 HOX genes are divided into 4 clusters (HOXA, HOXB, HOXC and HOXD) (9). Each HOX gene contains a well-conserved DNA sequence, known as the homeobox (10). The unique expression pattern, including mutation, and dependent mechanism of the HOX genes regulates, to some extent, the embryonic development of vertebrates (11,12). When HOX protein expression is upregulated, it may lead to cancer (5). It has also been reported that the HOXC gene family is highly expressed in certain solid tumors, including lung, prostate and colon cancer (13,14). The HOXA and HOXB gene families have a similar expression in breast cancer, which is derived from the ectoderm. Whether the expression level of the HOX gene follows the origin of the germ layer in cancer requires further investigation. A study has reported that *HOXC13*, a member of the HOXC gene family, is highly expressed in the MCF-7 cell line (15). Thus, the present study aimed to explore the expression and significance of *HOXC13* in breast cancer.

In the present study, the Oncomine and tumor public databases (bc-GenExMinerv 4.2; GOBO database; CCLE) were used to analyze the expression level of *HOXC13* in different types of cancer including breast cancer. *HOXC13* was then further investigated in breast cancer. The expression and co-expression of *HOXC13* in breast cancer was re-analyzed using the University of California, Santa Cruz (UCSC) cancer genomics browser. Finally, the clinical significance of *HOXC13* in breast cancer was further explored.

Correspondence to: Dr Wei Wei, Department of Breast Surgery, Shenzhen Hospital, Peking University, 1120 Lianhuabei Street, Shenzhen, Guangdong 518036, P.R. China
E-mail: rxwei1123@163.com

*Contributed equally

Key words: homeobox C13, breast cancer, bioinformatics, prognosis

Materials and methods

Oncomine database verification. The Oncomine (www.oncomine.org) database is a public bioinformatics database containing gene expression data set that has become an industry-standard tool cited in >1,100 peer-reviewed journal articles (16,17). The Oncomine platform has been used as a foundation for ground-breaking discoveries with unique features that include scalability, high quality, consistency and standardized analysis (18). In order to screen out the most meaningful RNA probes, the paired Student's t-test was used to generate P-values to compare expression differences between cancer and healthy adjacent non-cancerous tissues. Relevant statistical indicators were used as follows: $P < 1 \times 10^{-4}$, fold change >4 and gene ranking in the top 10%. Moreover, the Oncomine database was used to explore the co-expression analysis of *HOXC13* in breast cancer. The search term 'HOXC13' was used, followed by coexpression analysis and selecting the cancer type as breast cancer. Lastly, the database of TCGA breast was chosen. Furthermore, the same cut-off values used as aforementioned.

Cancer cell line encyclopedia (CCLE) verification. The CCLE (portals.broadinstitute.org) provides public access to genomic data, analysis and visualization for >1,100 cell lines from various tumors, such as gastric cancer cell line AGS and intestinal cancer cell line SW480 (19,20). Each gene of the human genome has multiple datasets and data identifiers, obtained by high-throughput sequencing. The 5 major dataset types are copy number, mRNA expression (Affymetrix), reverse phase protein array, reduced representation bisulfite sequencing, and mRNA expression (RNA sequencing). The expression and methylation level of *HOXC13* was analyzed in each tumor cell line using CCLE, using the search term 'HOXC13'.

Gene expression-based Outcome for Breast cancer Online (GOBO) analysis. The GOBO database (version 1.0.3; co.bmc.lu.se/gobo/gsa_cellines.pl) is a user-friendly public database. It allows for rapid assessment of gene expression levels, identification of co-expressed genes and association with outcome for single genes, gene sets or gene signatures in an 1,881-sample breast cancer dataset (21). The most important functionality of the GOBO database is the possibility of investigating gene expression levels in breast cancer subgroups and cell lines for gene sets (22). Breast cancer subtypes are classified into basal A, basal B and luminal in the GOBO database. A correlation map is a square table where each line and column represent a gene. Each cell represents an interaction between two genes and is colored according to the value of the Pearson's correlation coefficient between these two genes, from dark blue (coefficient=-1) to dark red (coefficient=1). Cells from the diagonal of the correlation map represent the interaction of a gene with itself and are colored black.

UCSCcancer genomics browser analysis. UCSC (xena.ucsc.edu) is an online exploration tool for public and private multi-omics functional genomics and clinical/phenotype data (23). The Cancer Genome Atlas (TCGA; <https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>) were used in the present study. Using the UCSC database,

a heat map of *HOXC13* expression in various subtypes of breast cancer, such as LuminalA, luminalB, normal-like, Basal-like and Her2-riched was generated. At the same time, the co-expression of *HOXC13* in breast cancer was analyzed.

cBioPortal database analysis. The public cBioPortal site (www.cbioportal.org; last entered, 28th March 2019) is hosted by the Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center. The cBioportal database has been recognized as a way to verify gene mutations (24-26). This database can also analyze gene expression in different tumors and different studies (23,27). This database has been recognized by multiple studies (26,28). The online cBioPortal for Cancer Genomics was used to provide mutations of *HOXC13* (including nonstart, missense, truncation and missense) and its expression in different studies (28). The cancer types and databases used were breast (TCGA2015), breast (TCGA), breast invasive carcinoma breast (TCGA PanCan) (29-34).

Breast cancer gene-expression miner (bc-GenExMiner) analysis. bc-GenExMiner (version 4.2) is a statistical mining tool of published annotated genomic data (35,36). The statistical analyses are grouped in three modules: Expression, prognosis and correlation. The co-expression of *HOXC13* in breast cancer was explored using this database; each study is validated across multiple databases to avoid discrepancies in individual databases. At the same time, the effects of *HOXC13* and HOX transcript antisense RNA (*HOTAIR*) on the survival prognosis in breast cancer were also analyzed.

Statistical analysis. Pearson test and Spearman's rank test were used to evaluate coexpression. The analysis criteria selected were as follows: Gene, nodal and estrogen receptor status of the cohorts to be explored, event on which survival analysis will be based and splitting criterion of median *HOXC13* expression. To analyze the prognostic value of *HOXC13* and *HOTAIR*, the patient samples are split into two groups according to the median expressions of *HOXC13* and *HOTAIR*. The two patient cohorts were compared by a Kaplan-Meier survival plot, and the hazard ratio with 95% confidence intervals and logrank P-value are calculated. Significance was determined by the P-value provided by each database.

Results

***HOXC13* mRNA expression in human cancer.** *HOXC13* has been proven to be highly expressed in digestive tract-derived tumors (37-39). However, to the best of our knowledge, there have been no reports on the expression of *HOXC13* in breast cancer. Therefore the expression levels of *HOXC13* in various human tumors from the Oncomine database and CCLE were determined. A simultaneous fold change of >4, gene rank of >10% and $P < 1 \times 10^{-4}$ was set as the threshold. To our surprise, *HOXC13* was found by high-throughput sequencing and biological gene chip technology to be abnormally highly expressed in breast cancer (Fig. 1A). Only breast cancer revealed significant unique analysis in the Oncomine database when the fold change was >4.

***HOXC13* mRNA expression in breast cancer.** The high expression of *HOXC13* in breast cancer has been preliminary




Figure 1. *HOXC13* mRNA expression level in different types of human cancer. This image shows the expression of *HOXC13* in human tumors. (A) Graph showing the number of datasets with a statistically significant mRNA *HOXC13* overexpression, based on the cut-off value of $P < 1 \times 10^{-4}$ and fold change > 4 in the OncoPrint database. The cell color is determined by the best gene rank percentile for the analyses within the cell. Blue represents low expression in tumors, red represents high expression in tumors and white represents no difference in tumor tissues and normal tissues. As shown in the figure, breast cancer has three data sets showing high expression, based on the cut-off value of $P < 1 \times 10^{-4}$, fold change > 4 and gene ranking in the top 10%. (B) mRNA expression of *HOXC13* in different cancer cell lines. The expression of *HOXC13* ranks highest in breast cancer using Affy gene chip data in the Cancer Cell Line Encyclopedia. (C) The mRNA expression of *HOXC13* ranks fourth highest in different tumor cell lines RNA-seq data, behind that of Ewings sarcoma, esophagus and upper aerodigestive tract. Affy, Affymetrix; RNA seq, RNA sequencing; CNS, central nervous system; *HOXC13*, homeobox C13.

confirmed in the OncoPrint database, GOBO database and CCLE. From the CCLE database, it was found that at the RNAseq level, the expression level of *HOXC13* in breast cancer ranked fourth and ranked first in the Affy level. However, there is no report on the specific expression of *HOXC13* in breast cancer. Therefore, its specific expression in various subtypes of breast cancer was further explored. *HOXC13* was analyzed in various tumor types via OncoPrint database and GOBO database and explored *HOXC13* in various breast cancer cells via GOBO database and CCLE. *HOXC13* was found to be highly expressed in invasive and luminal-like breast cancer than in any other subtype (Figs. 2 and 3). Such expression characteristics were consistent with breast cancer cell lines and tissues (Figs. 2D and 3). Using the UCSC cancer genomics browser analysis, the heat map of the gene and exon expression of *HOXC13* in various subtypes of breast cancer was obtained (Fig. 4A). Furthermore, the expression of *HOXC13* in the different data sets, including breast (TCGA 2015), breast (TCGA), breast invasive carcinoma breast (TCGA PanCan), was explored using the cBioPortal database. The expression characteristics of breast cancer in multiple data sets such as amplification and missense mutations, were demonstrated (Fig. 4B).

HOXC13 methylation and mutation in human breast cancer. The bubble chart shows the methylation level of *HOXC13* in breast cancer cell lines from the CCLE (Fig. 5A). *HOXC13* is highly methylated at three sites (positions 54,330,731, 54,330,950 and 54,330,957) on chromosome 12 from methylation and coverage (Fig. 5A). The discovery of CpG island methylation further supported the high expression of *HOXC13* in breast cancer. cBioPortal was used to assess the frequency of *HOXC13* mutations in breast cancer (Figs. 4B and 5). *HOXC13* contains multiple mutations in breast cancer such as amplification, gain, missense and truncation (Fig. 4B). Missense and truncation are two major forms of mutation (Fig. 5).

Co-expression of HOXC13 mRNA in breast cancer. To investigate the reason for the high expression of *HOXC13* in breast cancer, bc-GenExMiner version 4.2 was used to analyze the potential co-expression of *HOXC13* in breast cancer. It was found that *HOTAIR* and *HOXC13* are highly co-expressed in breast cancer (Fig. 6A). Furthermore, to verify the co-expression of *HOXC13* and *HOTAIR* in breast cancer, their co-expression heat maps were obtained and mined (Fig. 6B) and correlation analysis was performed using the UCSC Xena browser (Fig. 6C).




Figure 2. *HOXC13* expression analysis in different breast cancer subtypes. Box plots represent the expression of *HOXC13* in invasive breast cancer from the Oncomine database. (A) Invasive BC (invasive lobular breast carcinoma): P-value= 7.04×10^{-12} . (B) Invasive BC (invasive breast carcinoma): P-value= 1.05×10^{-16} . (C) Invasive BC (invasive ductal breast carcinoma): P-value= 2.67×10^{-23} . (D-E) Red represents breast cancer subtype basal A, gray represents breast cancer subtype basal B, and blue represents breast cancer subtype luminal. (D) Using GOBO analysis, in various subtypes of breast cancer, the *HOXC13* expression was significantly higher in luminal-like breast cancer: P=0.00017. (E) GOBO analysis showing the expression of *HOXC13* in each breast cancer cell line. BC, breast carcinoma; GOBO, Gene expression-based Outcome for Breast cancer Online; *HOXC13*, homeobox C13. The neve expression refers to the base two logarithm of the expression of the gene in each cell, and the neve intensity refers to the expression level of each breast cancer cell relative to the expression of the internal reference.




Figure 3. *HOXC13* expression analysis in breast cancer subtypes of SCM1 subtypes. (A) The box plot of *HOXC13* expression according to SCM1 subtypes from bc-GenExMiner version 4.2. (B) Group comparison in each subgroup of breast cancer, and corresponding statistical values in SCM1 subtypes. HER2, human epidermal growth factor receptor 2; Lum, luminal; *HOXC13*, homeobox C13; SCM, subtype clustering model.




Figure 4. Analysis of the expression of *HOXC13* in breast cancer subtypes. (A) *HOXC13* expression heatmap of each breast cancer subtype in TCGA from the University of California, Santa Cruz Xena browser. Null data indicates samples that have no gene expression data. (B) *HOXC13* expression analysis and mutation status in breast cancer using cBioPortal. *HOXC13* was significantly amplified in breast cancer subtypes, including breast invasive carcinoma. The present study included datasets on breast (TCGA2015), breast (TCGA) and breast invasive carcinoma breast (TCGA PanCan) datasets. TCGA, The Cancer Genome Atlas; RNA seq, RNA sequencing; HER2, human epidermal growth factor receptor 2; RPKM, reads per kilobase of transcript per million mapped reads; *HOXC13*, homeobox C13; VUS, variants of uncertain significance; CNA, copy number alteration.




Figure 5. Methylation and mutation status of *HOXC13* in breast cancer. (A) Methylation status of *HOXC13* in breast cancer cell lines. The x-axis displays the cell line in which methylation was measured. The y-axis displays the position of the methylation data. The number before the colon is the chromosome, and the number after the colon the position. Red, orange and blue represent high, medium and low levels of methylation. The size of the bubble represents coverage. (B) Mutation status of *HOXC13* in breast cancer from cBioPortal. The mutation types include nonstart, missense and truncation, and missense is shown as 1, 2, 3 and 4. The boxes in green and red represent the open reading frame. The scale shows where the mutation site is located in the sequence. Corresponding changed protein name contains M1, S242Y, X_246splice and S242Y. The data used included studies on breast cancer (29-34).




Figure 6. Co-expression analysis of *HOXC13* and *HOTAIR*. (A) A correlation map illustrates pairwise correlations between *HOXC13* and *HOTAIR*. They are all patients, ER+, ER-, luminal A, luminal B and basal-like respectively according to the group. (B) The co-expression heat map of *HOXC13* and *HOTAIR* in TCGA derived from the UCSC Xena browser. (C) Association between *HOXC13* and *HOTAIR* gene expression in TCGA breast cancer derived from the UCSC Xena browser. The Pearson's value was 0.7369 and the Spearman's value was 0.7048. *HOXC13*, homeobox C13; *HOTAIR*, HOX transcript antisense RNA; UCSC, University of California Santa Cruz; ER, estrogen receptor; -, negative; +, positive; TCGA, The Cancer Genome Atlas; RNA seq, RNA sequencing; HER2, human epidermal growth factor receptor 2; PAM, prediction analysis of microarray.

Impact of *HOXC13* and *HOTAIR* on the prognosis of patients with breast cancer. To verify the impact of the high expression of *HOXC13* and *HOTAIR* on patients with breast cancer, prognostic analysis of *HOXC13* and *HOTAIR* in breast cancer was performed and *HOXC13* and *HOTAIR* were found to have a negative impact on the prognosis of patients with tumor and lymph node metastasis (Fig. 7).

Discussion

The mammary gland is an appendage of the ectoderm, whose formation begins during embryonic development (40). Moreover, breast cancer cells remain highly associated with ectoderm cells (41). Studies have shown that the HOX gene plays an important role in embryonic development and tumor




Figure 7. Prognostic value of *HOXC13* and *HOTAIR* in breast cancer. (A) Prognostic analysis of *HOXC13* with regards to positive nodal status. The higher the expression of *HOXC13*, the shorter the AE-free survival time. (B) Prognostic analysis for *HOXC13* with regards to metastatic relapse. The higher the expression of *HOXC13*, the shorter the MR-free survival time. (C) Prognostic analysis for *HOTAIR* with regards to positive nodal status. The higher the expression of *HOTAIR*, the shorter the AE free survival time. (D) Prognostic analysis for *HOTAIR* with regards to metastatic relapse. The higher the expression of *HOTAIR*, the shorter the MR-free survival time. *HOTAIR*, *HOX* transcript antisense RNA; AE, any event; MR, metastatic relapse.

formation (9,42-44). However, to the best of our knowledge, no research has reported the exact role of *HOXC13* in breast cancer so far.

The *HOXC13* gene is considered an element of hair morphogenesis, and the *HOXC13* protein is a member of the human replication complex in growing cells (45,46). This is the same for breast adenocarcinoma MCF7 lines (46). *HOXC13* can promote the expression of a series of proto-oncogenes, including topoisomerase I and II, and allow these expression products to form a replication complex (47,48). Therefore, *HOXC13* is involved in the development of tumors. In addition, *HOXC13* increases the metastasis of ectodermal-derived melanoma (49). *HOTAIR* is the product of the transcription of the *HOXC* gene cluster antisense strand (50). *HOTAIR* is transcribed from the mammalian *HOXC* gene cluster on chromosome 12q13.13 (51,52). *HOTAIR* predicts poor prognosis in tumor cell cycle and metastasis (53). It has been reported that *HOTAIR* upregulates *HOX* in colon cancer (39). A strong co-expression of *HOTAIR* and *HOXC13* was confirmed in proximal and distal colon cancer, suggesting that *HOTAIR*

and *HOXC13* could promote tumor and lymph node metastasis (39,54-56).

In the present study, it was first identified that *HOXC13* is highly expressed in breast cancer both at the cellular and tissue levels. This was a finding from the co-verification of the data from TCGA's OncoPrint or GSE's bc-GenExMiner. It was found for the first time that *HOXC13* is most highly expressed in luminal-like subtype of breast cancer. This laid the foundation for the future study of the relationship between *HOXC13* and breast cancer surface hormone receptors (estrogen receptor and progesterone receptor). In order to explore the high expression of *HOXC13* in breast cancer, its methylation and mutation status were investigated. To our surprise, three sites on chromosome 12 were found to be consistently highly methylated in different breast cancer cell lines. Certain studies have reported that *HOX* gene methylation regulates hereditary breast cancer (57-59). In addition, the methylation level of *HOXA11* is significantly higher in breast cancer compared with that in normal tissues, and is positively associated with family history and lymph node metastasis in breast cancer (59). Furthermore,

the methylation level of *HOXD13* in breast cancer is almost identical to that of *HOXA11*, and leads to shorter survival time (58). Therefore, the present findings and the HOX gene family have consistent trends in methylation levels and similar prognostic effects in breast cancer. However, further studies on the specific regulation mechanism of *HOXC13* methylation in *HOXC13* transcription is required. The present study is the first to report the mutation of *HOXC13* in breast cancer. Missense may be an indispensable cause of the high expression of *HOXC13* in breast cancer.

The lncRNA *HOTAIR* is derived from the region between *HOXC11* and *HOXC12* (51). It has been shown that *HOXC10*, *HOXC11*, *HOXC12* and *HOXC13* are adjacent to each other in the *HOXC* gene cluster (52). Simultaneously, the *HOXC* distal enhancer has non-specific enhancement of *HOXC10* and *HOTAIR* enhancer activity, promoting the *HOXC10* and *HOTAIR* expression (60). On the other hand, specific intergenic non-coding RNAs (including *HOTAIR*) in the HOX loci can directly modulate the expression of the HOX gene in normal and cancer status (61). This has been confirmed in colon cancer (39,55). Therefore the mechanism between *HOXC13* and *HOTAIR* will be explored further in this respect. In the present study, the co-expression of *HOTAIR* and *HOXC13* provided a new direction for studying the function of *HOTAIR* in breast cancer. In addition, a study has identified through meta-analysis that *HOTAIR* has a statistically significant effect on lymph node and distant metastasis in various types of cancer, including breast cancer, gastric cancer and colorectal cancer, which was consistent with our conclusion (62). The present data showed that *HOTAIR* and *HOXC13* were significantly associated with lymph node metastasis and distant metastasis recurrence. Furthermore, they were shown to have a significant impact on survival period.

In conclusion, the present study was performed using public databases and revealed the expression and clinical significance of *HOXC13* in breast cancer. However, the specific interactions and mechanisms involved require further experimental verification, which will be performed in future studies.

Acknowledgements

Not applicable.

Funding

This study was supported by the Shenzhen Science and Research Innovation Foundation (grant no. JCYJ20170815090309586).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

WW contributed to the experimental design and fundraising. JWC and LZ contributed to the acquisition of data. LZZ assisted in the data processing. CL processed the data and wrote the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Barrios CH, Reinert T and Werutsky G: Global breast cancer research: Moving forward. *Am Soc Clin Oncol Educ Book* 38: 441-450, 2018.
- Harbeck N and Gnant M: Breast cancer. *Lancet* 389: 1134-1150, 2017.
- Nathanson KL and Domchek SM: Therapeutic approaches for women predisposed to breast cancer. *Annu Rev Med* 62: 295-306, 2011.
- Rousset-Jablonski C and Gompel A: Screening for familial cancer risk: Focus on breast cancer. *Maturitas* 105: 69-77, 2017.
- Luo Z, Rhie SK and Farnham PJ: The enigmatic HOX genes: Can we crack their code? *Cancers (Basel)* 11: pii: E323, 2019.
- Turcotte M, Abadi A, Peralta-Romero J, Suarez F, Reddon H, Gomez-Zamudio J, Burguete-Garcia AI, Cruz M and Meyre D: Genetic contribution to waist-to-hip ratio in Mexican children and adolescents based on 12 loci validated in European adults. *Int J Obes (Lond)* 43: 13-22, 2019.
- Liu F, Chen Y, Zhu G, Hysi PG, Wu S, Adhikari K, Breslin K, Pospiech E, Hamer MA, Peng F, *et al*: Meta-analysis of genome-wide association studies identifies 8 novel loci involved in shape variation of human head hair. *Hum Mol Genet* 27: 559-575, 2018.
- Li L, Wang Y, Song G, Zhang X, Gao S and Liu H: HOX cluster-embedded antisense long non-coding RNAs in lung cancer. *Cancer Lett* 450: 14-21, 2019.
- Bhatlekar S, Fields JZ and Boman BM: Role of HOX genes in stem cell differentiation and cancer. *Stem Cells Int* 2018: 3569493, 2018.
- Vaquerizas JM, Kummerfeld SK, Teichmann SA and Luscombe NM: A census of human transcription factors: Function, expression and evolution. *Nat Rev Genet* 10: 252-263, 2009.
- Gordon J: Hox genes in the pharyngeal region: How Hoxa3 controls early embryonic development of the pharyngeal organs. *Int J Dev Biol* 62: 775-783, 2018.
- Mallo M: The vertebrate tail: A gene playground for evolution. *Cell Mol Life Sci*, Sep 26, 2019 (Epub ahead of print).
- Bhatlekar S, Fields JZ and Boman BM: HOX genes and their role in the development of human cancers. *J Mol Med (Berl)* 92: 811-823, 2014.
- Yao Y, Luo J, Sun Q, Xu T, Sun S, Chen M, Lin X, Qian Q, Zhang Y, Cao L, *et al*: HOXC13 promotes proliferation of lung adenocarcinoma via modulation of CCND1 and CCNE1. *Am J Cancer Res* 7: 1820-1834, 2017.
- Svingen T and Tonissen KF: Altered HOX gene expression in human skin and breast cancer cells. *Cancer Biol Ther* 2: 518-523, 2003.
- Shi S and Zhang ZG: Role of Sp1 expression in gastric cancer: A meta-analysis and bioinformatics analysis. *Oncol Lett* 18: 4126-4135, 2019.
- Cheng L, Shi L and Dai H: Bioinformatics prognostic biomarkers among Krüppel-like transcription factors (KLFs) in breast cancer. *Cancer Biomark*, Oct 12, 2019 (Epub ahead of print).
- Yang K, Gao J and Luo M: Identification of key pathways and hub genes in basal-like breast cancer using bioinformatics analysis. *Onco Targets Ther* 12: 1319-1331, 2019.
- Cheng L, Pandya PH, Liu E, Chandra P, Wang L, Murray ME, Carter J, Ferguson M, Saadatzaheh MR, Bijangi-Visheshsaraei K, *et al*: Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma. *BMC Med Genomics* 12 (Suppl 1): S23, 2019.

20. Streit M, Gratzl S, Stitz H, Wernitznig A, Zichner T and Haslinger C: Ordino: A visual cancer analysis tool for ranking and exploring genes, cell lines and tissue samples. *Bioinformatics* 35: 3140-3142, 2019.
21. Fernández-Nogueira P, Bragado P, Almendro V, Ametller E, Rios J, Choudhury S, Mancino M and Gascón P: Differential expression of neurogenes among breast cancer subtypes identifies high risk patients. *Oncotarget* 7: 5313-5326, 2016.
22. Zeng, Xiao Y, Zhu J, Peng C, Liang W and Lin H: Knockdown of nucleophosmin 1 suppresses proliferation of triple-negative breast cancer cells through activating CDH1/Skp2/p27kip1 pathway. *Cancer Manag Res* 11: 143-156, 2018.
23. Klonowska K, Czubak K, Wojciechowska M, Handschuh L, Zmienko A, Figlerowicz M, Dams-Kozłowska H and Kozłowski P: Oncogenomic portals for the visualization and analysis of genome-wide cancer data. *Oncotarget* 7: 176-192, 2016.
24. Wen W, Gong J, Wu P, Zhao M, Wang M, Chen H and Sun J: Mutations in gliclazide-associated genes may predict poor bladder cancer prognosis. *FEBS Open Bio* 9: 457-467, 2019.
25. Chen E, Qin X, Peng K, Xu X, Li W, Cheng X, Tang C, Cui Y, Wang Z and Liu T: Identification of potential therapeutic targets among CXc chemokines in breast tumor microenvironment using integrative bioinformatics analysis. *Cell Physiol Biochem* 45: 1731-1746, 2018.
26. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, *et al*: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2: 401-404, 2012.
27. Kline CLB, Ralff MD, Lulla AR, Wagner JM, Abbosh PH, Dicker DT, Allen JE and El-Deiry WS: Role of dopamine receptors in the anticancer activity of ONC201. *Neoplasia* 20: 80-91, 2018.
28. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, *et al*: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal* 6: pii, 2013.
29. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, *et al*: Sequence analysis of mutations and translocations across breast cancer subtypes. *Nature* 486: 405-409, 2012.
30. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, Gelmon K, Chia S, Mar C, Wan A, *et al*: Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. *Nature* 518: 422-426, 2015.
31. Martelotto LG, De Filippo MR, Ng CK, Natrajan R, Fuhrmann L, Cyrta J, Piscuoglio S, Wen HC, Lim RS, Shen R, *et al*: Genomic landscape of adenoid cystic carcinoma of the breast. *J Pathol* 237: 179-189, 2015.
32. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, *et al*: The genomic landscape of endocrine-resistant advanced breast cancers. *Cancer Cell* 34: 427-438.e6, 2018.
33. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, *et al*: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. *Nature* 486: 395-399, 2012.
34. Tan J, Ong CK, Lim WK, Ng CC, Thike AA, Ng LM, Rajasegaran V, Myint SS, Nagarajan S, Thangaraju S, *et al*: Genomic landscapes of breast fibroepithelial tumors. *Nat Genet* 47: 1341-1345, 2015.
35. Jézéquel P, Campone M, Gouraud W, Guérin-Charbonnel C, Leux C, Ricolleau G and Campion L: bc-GenExMiner: An easy-to-use online platform for gene prognostic analyses in breast cancer. *Breast Cancer Res Treat* 131: 765-775, 2012.
36. Jézéquel P, Frénel JS, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G and Campone M: bc-GenExMiner 3.0: New mining module computes breast cancer gene expression correlation analyses. *Database (Oxford)* 2013: bas060, 2013.
37. Luo J, Wang Z, Huang J, Yao Y, Sun Q, Wang J, Shen Y, Xu L and Ren B: HOXC13 promotes proliferation of esophageal squamous cell carcinoma via repressing transcription of CASP3. *Cancer Sci* 109: 317-329, 2018.
38. Marcinkiewicz KM and Gudas LJ: Altered histone mark deposition and DNA methylation at homeobox genes in human oral squamous cell carcinoma. *J Cell Physiol* 229: 1405-1416, 2014.
39. Tatangelo F, Di Mauro A, Scognamiglio G, Aquino G, Lettieri A, Delrio P, Avallone A, Cantile M and Botti G: Posterior HOX genes and HOTAIR expression in the proximal and distal colon cancer pathogenesis. *J Transl Med* 16: 350, 2018.
40. Robinson GW: Identification of signaling pathways in early mammary gland development by mouse genetics. *Breast Cancer Res* 6: 105-108, 2004.
41. Tickle C, Crawley A and Goodman M: Mechanisms of invasiveness of epithelial tumours: Ultrastructure of the interactions of carcinoma cells with embryonic mesenchyme and epithelium. *J Cell Sci* 33: 133-155, 1978.
42. Morgan R and El-Tanani M: HOX genes as potential markers of circulating tumour cells. *Curr Mol Med* 16: 322-327, 2016.
43. Kamkar F, Xaymardan M and Asli NS: Hox-mediated spatial and temporal coding of stem cells in homeostasis and neoplasia. *Stem Cells Dev* 25: 1282-1289, 2016.
44. Nunes FD, de Almeida FC, Tucci R and de Sousa SC: Homeobox genes: A molecular link between development and cancer. *Pesqui Odontol Bras* 17: 94-98, 2003.
45. Godwin AR and Capocchi MR: Hoxc13 mutant mice lack external hair. *Genes Dev* 12: 11-20, 1998.
46. Comelli L, Marchetti L, Arosio D, Riva S, Abdurashidova G, Beltram F and Falaschi A: The homeotic protein HOXC13 is a member of human DNA replication complexes. *Cell Cycle* 8: 454-459, 2009.
47. La Starza R, Trubia M, Crescenzi B, Matteucci C, Negrini M, Martelli MF, Pelicci PG and Mecucci C: Human homeobox gene HOXC13 is the partner of NUP98 in adult acute myeloid leukemia with t(11;12)(p15;q13). *Genes Chromosomes Cancer* 36: 420-423, 2003.
48. Gurevich RM, Aplan PD and Humphries RK: NUP98-topoisomerase I acute myeloid leukemia-associated fusion gene has potent leukemogenic activities independent of an engineered catalytic site mutation. *Blood* 104: 1127-1136, 2004.
49. Cantile M, Scognamiglio G, Anniciello A, Farina M, Gentilcore G, Santonastaso C, Fulciniti F, Cillo C, Franco R, Ascierto PA and Botti G: Increased HOX C13 expression in metastatic melanoma progression. *J Transl Med* 10: 91, 2012.
50. Woo CJ and Kingston RE: HOTAIR lifts noncoding RNAs to new levels. *Cell* 129: 1257-1259, 2007.
51. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Bruggmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E and Chang HY: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. *Cell* 129: 1311-1323, 2007.
52. Li J, Wang J, Zhong Y, Guo R, Chu D, Qiu H and Yuan Z: HOTAIR: A key regulator in gynecologic cancers. *Cancer Cell Int* 17: 65, 2017.
53. Zhang JX, Han L, Bao ZS, Wang YY, Chen LY, Yan W, Yu SZ, Pu PY, Liu N, You YP, *et al*: HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. *Neuro Oncol* 15: 1595-1603, 2013.
54. Zhao W, An Y, Liang Y and Xie XW: Role of HOTAIR long noncoding RNA in metastatic progression of lung cancer. *Eur Rev Med Pharmacol Sci* 18: 1930-1936, 2014.
55. Weidle UH, Birzele F, Kollmorgen G and Ruger R: Long non-coding RNAs and their role in metastasis. *Cancer Genomics Proteomics* 14: 143-160, 2017.
56. Zhou Y, Zhang Y, Yang Y, Xiang J and Chen Z: Candidate genes involved in metastasis of colon cancer identified by integrated analysis. *Cancer Med* 8: 2338-2347, 2019.
57. Pilato B, Pinto R, De Summa S, Lambo R, Paradiso A and Tommasi S: HOX gene methylation status analysis in patients with hereditary breast cancer. *J Hum Genet* 58: 51-53, 2013.
58. Zhong Z, Shan M, Wang J, Liu T, Xia B, Niu M, Ren Y and Pang D: HOXD13 methylation status is a prognostic indicator in breast cancer. *Int J Clin Exp Pathol* 8: 10716-10724, 2015.
59. Xia B, Shan M, Wang J, Zhong Z, Geng J, He X, Vu T, Zhang D and Pang D: Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer. *Oncotarget* 8: 9794-9805, 2017.
60. Milevskiy MJ, Al-Ejeh F, Saunus JM, Northwood KS, Bailey PJ, Betts JA, McCart Reed AE, Nephew KP, Stone A, Gee JM, *et al*: Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer. *Hum Mol Genet* 25: 3269-3283, 2016.
61. Botti G, De Chiara A, Di Bonito M, Cerrone M, Malzone MG, Collina F and Cantile M: Noncoding RNAs within the HOX gene network in tumor pathogenesis and progression. *J Cell Physiol* 234: 395-413, 2018.
62. Sun Z, Wu XY and Wu CL: The association between lncRNA HOTAIR and cancer lymph node metastasis and distant metastasis: A meta-analysis. *Neoplasma* 65: 178-184, 2018.

